These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14670323)

  • 1. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine.
    Qadri F; Ahmed T; Wahed MA; Ahmed F; Bhuiyan NA; Rahman AS; Clemens JD; Black RE; Albert MJ
    Vaccine; 2004 Jan; 22(3-4):416-21. PubMed ID: 14670323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine.
    Albert MJ; Qadri F; Wahed MA; Ahmed T; Rahman AS; Ahmed F; Bhuiyan NA; Zaman K; Baqui AH; Clemens JD; Black RE
    J Infect Dis; 2003 Mar; 187(6):909-13. PubMed ID: 12660937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation.
    Ahmed T; Arifuzzaman M; Lebens M; Qadri F; Lundgren A
    Vaccine; 2009 Dec; 28(2):422-9. PubMed ID: 19837094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children.
    Qadri F; Wennerâs C; Ahmed F; Asaduzzaman M; Saha D; Albert MJ; Sack RB; Svennerholm A
    Vaccine; 2000 Jun; 18(24):2704-12. PubMed ID: 10781858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1994 Sep; 12(12):1078-82. PubMed ID: 7998416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation.
    Karlsen TH; Sommerfelt H; Klomstad S; Andersen PK; Strand TA; Ulvik RJ; Ahrén C; Grewal HM
    Infect Immun; 2003 Jul; 71(7):3909-13. PubMed ID: 12819076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera.
    Clemens JD; van Loon F; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; Khan MR; Yunus M; Huda S
    J Infect Dis; 1991 Jun; 163(6):1235-42. PubMed ID: 2037789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children.
    Saha A; Chowdhury MI; Nazim M; Alam MM; Ahmed T; Hossain MB; Hore SK; Sultana GN; Svennerholm AM; Qadri F
    Vaccine; 2013 Jan; 31(4):647-52. PubMed ID: 23200936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.
    Clemens JD; Stanton BF; Chakraborty J; Sack DA; Khan MR; Huda S; Ahmed F; Harris JR; Yunus M; Khan MU
    J Infect Dis; 1987 Jan; 155(1):79-85. PubMed ID: 3540139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines.
    Clemens JD; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; van Loon F; Khan MR; Yunis M; Huda S
    Vaccine; 1990 Oct; 8(5):469-72. PubMed ID: 2251873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired mucosal antibody response to cholera toxin in vitamin A-deficient rats immunized with oral cholera vaccine.
    Wiedermann U; Hanson LA; Holmgren J; Kahu H; Dahlgren UI
    Infect Immun; 1993 Sep; 61(9):3952-7. PubMed ID: 8359917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunization with cholera toxin provides protection against Campylobacter jejuni in an adult mouse intestinal colonization model.
    Albert MJ; Mustafa AS; Islam A; Haridas S
    mBio; 2013 May; 4(3):e00246-13. PubMed ID: 23653448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin.
    Migasena S; Desakorn V; Suntharasamai P; Pitisuttitham P; Prayurahong B; Supanaranond W; Black RE
    Infect Immun; 1989 Jan; 57(1):117-20. PubMed ID: 2909484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh.
    Sack DA; Clemens JD; Huda S; Harris JR; Khan MR; Chakraborty J; Yunus M; Gomes J; Siddique O; Ahmed F
    J Infect Dis; 1991 Aug; 164(2):407-11. PubMed ID: 1856488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.
    Akhtar M; Qadri F; Bhuiyan TR; Akter S; Rafique TA; Khan A; Islam LN; Saha A; Svennerholm AM; Lundgren A
    Vaccine; 2017 Jan; 35(2):321-328. PubMed ID: 27916412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1992; 10(2):130-2. PubMed ID: 1539466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.